Biocon Launches Yesafili™ Biosimilar Aflibercept in the United States

What Happened ?

Biocon Limited announced the commercial launch of Yesafili™ (aflibercept-jbv) in the United States on August 3, 2026. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor biosimilar to its reference product EYLEA® (aflibercept) 2 mg. The product was previously approved and granted interchangeable designation by the U.S. FDA in May 2024, allowing substitution at the pharmacy level in accordance with state laws.

key details

• Product Name: Yesafili™ (aflibercept-jbv)
• Category: Biosimilar (interchangeable)
• Reference Product: EYLEA® (aflibercept) 2 mg
• Launch Date: August 3, 2026
• Market: United States (international)
• Indications: Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR)
• FDA Status: Approved in May 2024; granted interchangeable designation allowing pharmacy-level substitution

Note:

• Approval based on comprehensive analytical, nonclinical, and clinical data confirming Yesafili is highly similar to Eylea® 2 mg. Phase 3 INSIGHT Study demonstrated no clinically meaningful differences in pharmacokinetics, safety, efficacy, and immunogenicity.

Risk Analysis

Summary:

• While the US launch of Yesafili™ presents significant market opportunity, risks include competitive landscape, regulatory changes, and market adoption dynamics.

Key Risks:

• Intense competition in the biosimilar ophthalmology space, including from other biosimilar entrants.
• Market adoption may be slower than anticipated due to physician prescribing patterns and payer reimbursement dynamics.
• Regulatory changes or patent litigation could impact market access.
• Manufacturing or supply chain disruptions could affect commercial availability.
• Currency fluctuation between USD and INR could impact revenue realization.

Worst Case:

• Slower-than-expected market adoption or pricing pressure from competitors could result in lower-than-projected revenue contribution from Yesafili™.

Risk Level: Medium

Company Commentary

Management highlighted that:

• Shreehas Tambe, CEO & Managing Director, Biocon Ltd: “The launch of Yesafili™ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions.”
• “This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea® 2 mg, advancing access to life-changing medicines for patients around the world.”